Pharmaceutical Product Development

About: Pharmaceutical Product Development is a company organization based out in Wilmington, North Carolina, United States. It is known for research contribution in the topics: Immunotoxin & Fusion protein. The organization has 402 authors who have published 353 publications receiving 16396 citations.

Fine Tuning Antibody Conjugation Methods using SNAP-tag Technology.

Abstract: Background Targeted imaging and therapy (theranostics) is a promising approach for the simultaneous improvement of cancer diagnosis, prognosis and management. Therapeutic and imaging reagents are coupled to tumor-targeting molecules such as antibodies, providing a basis for truly personalized medicine. However, the development of antibody-drug conjugates with acceptable pharmaceutical properties is a complex process and several parameters must be optimized, such as the controlled conjugation method and the drug-to-antibody ratio. Objective The major aim of this work is to address fundamental key challenges for the development of versatile technology platform for generating homogenous immunotheranostic reagent. Method We conjugated the theranostics reagent IRDye700dx to a recombinant antibody fusion protein containing a self-labeling protein (SNAP-tag) which provides a unique reaction site. Results The resulting conjugate was suitable for the imaging of cancer cells expressing the epidermal growth factor receptor and demonstrated potent phototherapeutic and imaging activities against them. Conclusion Here, we describe a simple, rapid and robust site-directed labeling method that can be used to generate homogeneous immunoconjugate with defined pharmacological properties.

Highlighting the challenge of delayed overall survival (OS) curve separation in immunotherapy clinical trials.

Abstract: 3009 Background: Cancer immunotherapy holds great potential but can elicit delayed responses, unlike chemotherapy. A delay in the separation of OS curves (between the control and treatment arms) ha...

Plasma proteomic analysis in patients with obstructive sleep apnea syndrome

Abstract: Proteomics is one of the strategies to evaluate molecular mechanisms underlying obstructive sleep apnea syndrome (OSAS). To examine the pathophysiological significance of plasma proteomics in OSAS, the plasma samples from severe OSAS patients (n = 6) with obese (BMI > 30) and non-OSAS patients (n = 6) with non-obese (BMI < 30) were subjected to proteomic profiling. Many proteins regarding inflammation and immune response, including complement proteins, two acute-phase reactants ceruloplasmin and serum amyloid P-component, were found to be highly expressed in severe OSAS patients. Protein changes responsible for immune modulation and inflammation may be a feature of OSAS patients.